Evotec SE (WBO:EVT) Short-Term Debt & Capital Lease Obligation : €149.1 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Evotec SE Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Evotec SE's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €149.1 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Evotec SE's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €477.1 Mil.

Evotec SE Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Evotec SE's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Short-Term Debt & Capital Lease Obligation Chart

Evotec SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

20.73

30.01

50.61

16.38

149.10

Evotec SE Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															14.11	16.38	-	144.29	149.10

Evotec SE Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Evotec SE Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Evotec SE's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Evotec SE (WBO:EVT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (WBO:EVT) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

EVO:USA EVOTF:USA 1EVT:Italy EVTd:UK 0IRF:UK EVT:Germany

Address

Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419

Website

https://www.evotec.com

Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.

Evotec SE (WBO:EVT) Headlines

From GuruFocus

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND's Dividend Analysis

By GuruFocus Research • 01-22-2024

Unveiling the Dividend Performance of EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND (EVT)

By GuruFocus Research • 09-21-2023

Eaton Vance Tax-Advantaged Dividend Income Fund January 2021 Distribution

By PRNewswire PRNewswire • 01-15-2021

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND's Dividend Analysis

By GuruFocus Research • 10-20-2023